Clinical information
BRAF
Somatic mutations in BRAF have been found in 37-50% of all malignant melanomas (mycancergenome.org). Multiple effective first-line systemic treatment options are available for patients with advanced BRAF-mutated melanoma including BRAF/MEK as well as PD-L1 inhibitors. Current guidelines recognize the importance of BRAF V600 testing for patients with metastatic disease recommending BRAF mutation status assessment.1
- 1National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Melanoma - Version 2.2018, available from https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf (accessed June 2018); Dummer et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2016; Suppl 5:126–132, Garbe et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-update 2016. Eur J Cancer 2016; 63:201–217.
BRAF Mutation Test
Our IdyllaTM BRAF Mutation Test provides fast, reliable information on the BRAF tumor mutation status reducing the clinical turnaround time significantly.
The IdyllaTM BRAF Mutation Test only requires 1 tissue section (5-10 µm) per sample and independent studies have shown that the test is able to detect mutations in samples with as low as 2% neoplastic cells. Even for challenging samples with high melanin content the IdyllaTM BRAF Mutation Test ensures conistent high sensitivity and accuracy.1
- 1Bisshop et al. Melanoma Research 2018, 28(2): 96–104.